Phenylbutyric acid: Simple structure-multiple effects

Current Pharmaceutical Design

Volumn 21, Issue 16, 2015, Pages 2147-2166

  Kusaczuk, Magdalena ^a   Bartoszewicz, Marek ^b   Cechowska Pasko, Marzanna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Ammonia scavenger; Butyric acid; Chemical chaperone; ER stress; Histone deacetylase inhibitor; Phenylbutyrate

Indexed keywords

AMMONIA; BUTYRIC ACID DERIVATIVE; CHAPERONE; HISTONE DEACETYLASE INHIBITOR; PHENYLBUTYRIC ACID; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; 4-PHENYLBUTYRIC ACID; ARYLBUTYRIC ACID DERIVATIVE;

ARTICLE; CANCER CELL; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; INFLAMMATION; NERVE DEGENERATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; APOPTOSIS; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; NEURODEGENERATIVE DISEASES; PATHOLOGY;

ANIMALS; APOPTOSIS; COLONIC NEOPLASMS; HUMANS; NEURODEGENERATIVE DISEASES; PHENYLBUTYRATES;

EID: 84929455627     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150105160059     Document Type: Article

References (174)

1. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21: 793-8.
2. Parodi PW. Cows’ milk fat components as potential anticarcinogenic agents. J Nutr 1997; 127: 1055-60.
3. Newmark HL, Young CW. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem 1995; 22: 247-53.
4. Goncalves P, Araujo JR, Martel F. Characterization of butyrate uptake by nontransformed intestinal epithelial cell lines. J Membr Biol 2011; 240: 35-46.
5. Berni Canani R, Di Costanzo M, Leone L, Pedata M, Meli R, Calignano, A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011; 17(12): 1519-28.
6. Macfarlane GT, Macfarlane S. Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol 2011; 45: S120-7.
7. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-19.
8. Hamer HM, Jonkers DM, Bast A, et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 2009; 28: 88-93.
9. Davis T, Kennedy C, Chiew YE, Clarke CL, DeFazio A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer 2000; 6: 4334-42.
10. Pineau T, Hudgins WR, Liu L, et al. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs Biochem Pharmacol 1996; 52: 659-67.
11. Darmaun D, Welch S, Rini A, Sager BK, Altomare A, Haymond MW. Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism. Am J Physiol 1998; 274: 801-7.
12. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15: 474-9.
13. Redonnet-Vernhet I, Rouanet F, Pedespan JM, Hocke C, Parrot F. A successful pregnancy in a heterozygote for OTC deficiency treated with sodium phenylbutyrate. Neurology 2000; 54: 1008.
14. Lee B, Rhead W, Diaz GA, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab 2010; 100(3): 221-8.
15. Lichter-Konecki U, Diaz GA, Merritt JL, et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab 2011; 103(4): 323-9.
16. Smith W, Diaz GA, Lichter-Konecki U, et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr 2013; 162(6): 1228-34.
17. Diaz GA, Krivitzky LS, Mokhtarani M, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology 2013; 57(6): 2171-9.
18. Dover GJ, Brusilow SW, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate [letter 29]. N Engl J Med 1992; 327: 569.
19. Perrine SP. Fetal globin stimulant therapies in the betahemoglobinopathies: principles and current potential. Pediatr Ann 2008; 37(5): 339-46.
20. Dover GJ, Brusilow SW, Charache S. Induction of HbF production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994; 84: 339.
21. Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7: 2292-300.
22. Zhang X, Wei L, Yang Y, Yu Q. Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway. J Cell Biochem 2004; 93(4): 819-29.
23. Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2’-deoxy-cytidine and different histone deacetylase inhibitors on human Ewing’s sarcoma cells. Cancer Cell Int 2008; 8: 16.
24. Guilloteau P, Martin L, Eeckhaut V, Ducatelle R, Zabielski R, Van Immerseel F. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev 2010; 23: 366-84.
25. Miyoshi M, Sakaki H, Usami M, et al. Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clin Nutr 2011; 30: 252-8.
26. Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D 2011; 11(3): 227-49.
27. Wiley JC, Meabon JS, Frankowski H, et al. Phenylbutyric acid rescues endoplasmic reticulum stress-induced suppression of APP proteolysis and prevents apoptosis in neuronal cells. PLoS ONE 2010; 5(2): e9135.
28. Kubota K, Niinuma Y, Kaneko M, et al. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J Neurochem 2006; 97(5): 1259-68.
29. Mimori S, Okuma Y, Kaneko M, et al. Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress. Biol Pharm Bull 2012; 35(1): 84-90.
30. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing DF508-CFTR. J Clin Invest 1997; 100: 2457-65.
31. Ono K, Ikemoto M, Kawarabayashi T, et al. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. Parkinsonism Relat Disord 2009; 15(9): 649-54.
32. Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer’s disease-like phenotype of a commonly used mouse model. Curr Pharm Des 2013; 19(28): 5076-84.
33. Phuphanich S, Baker SD, Grossman SA, et al. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol 2005; 7(2): 177-82.
34. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 2007; 25: 131-8.
35. Carducci MA, Nelson JB, Chan-Tack KM, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996; 2: 379-87.
36. Huang Y, Horvath CM, Waxman S. Regrowth of 5-fluorouraciltreated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate. Cancer Res 2000; 60: 3200-6.
37. Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P, Ekström TJ. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 2003; 22: 579-88.
38. Li LZ, Deng HX, Lou WZ, et al. Growth inhibitory effect of 4-phenyl butyric acid on human gastric cancer cells is associated with cell cycle arrest. World J Gastroenterol 2012; 18(1): 79-83.
39. Kormanik K, Kang H, Cuebas D, Vockley J, Mohsen AW. Evidence for involvement of medium chain acyl-CoA dehydrogenase in the metabolism of phenylbutyrate. Mol Genet Metab 2012; 107(4): 684-9.
40. Takai N, Narahara H. Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol 2010; 2010: 458431.
41. Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 2007; 4(5): 337-43.
42. Wang X, Wei X, Pang Q, Yi F. Histone deacetylases and their inhibitors: molecular mechanisms and therapeutic implications in diabetes mellitus. Acta Pharm Sin B 2012; 2(4): 387-95.
43. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1(1): 19-25.
44. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007; 321: 892-901.
45. Wang Z, Leng Y, Tsai LK, Leeds P, Chuang DM. Valproic acid attenuates blood–brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 2011; 31: 52-7.
46. Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? World J Gastroenterol 2013; 19(8): 1173-81.
47. Gao SM, Chen CQ, Wang LY, et al. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Exp Hematol 2013; 41(3): 261-70.
48. Lin J, Gilbert J, Rudek MA, et al. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 2009; 15(19): 6241-9.
49. Ohta M, Abe A, Ohno F, et al. Positive and negative regulation of podoplanin expression by TGF-β and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines. Oral Oncol 2013; 49(1): 20-6.
50. Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res 2000; 6(2): 681-92.
51. Kennedy C, Byth K, Clarke CL, deFazio A. Cell proliferation in the normal mouse mammary gland and inhibition by phenylbutyrate. Mol Cancer Ther 2002; 1(12): 1025-33.
52. Wang CT, Meng M, Zhang JC, et al. Growth inhibition and gene induction in human hepatocellular carcinoma cell exposed to sodium 4-phenylbutanoate. Chin Med J (Engl) 2008; 121(17): 1707-11.
53. Liu L, Hudgins WR, Miller AC, Chen L-H, Samid D. Transcriptional up-regulation of TGF-alpha by phenylactate and phenylbutyrate is associated with differentiation of human melanoma cells. Cytokine 1995; 7: 449-56.
54. Goh M, Chen F, Paulsen MT, Yeager AM, Dyer ES, Ljungman M. Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia 2001; 3(4): 331-8.
55. Hattori Y, Fukushima M, Maitani Y. Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth. Int J Oncol 2007; 30: 1427-39.
56. Lopez C, Feng FY, Herman JM, Nyati MK, Lawrence TS, Ljungman M. Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. Int J Radiat Oncol Biol Phys 2007; 69(1): 214-20.
57. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153(4): 657-68.
58. de Conti A, Tryndyak V, Koturbash I, et al. The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway. Carcinogenesis 2013; 34(8): 1900-6.
59. Kuroiwa-Trzmielina J, de Conti A, Scolastici C, et al. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 2009; 124(11): 2520-7.
60. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22(2): 181-5.
61. Ammerpohl O, Trauzold A, Schniewind B, et al. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 2007; 96: 73-81.
62. Carducci MA, Gilbert J, Bowling MK, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001; 7: 3047-55.
63. Schultz J, Ibrahim SM, Vera J, Kunz M. 14-3-3σ gene silencing during melanoma progression and its role in cell cycle control and cellular senescence. Mol Cancer 2009; 8: 53.
64. Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 2007; 67(1): 346-53.
65. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125: 2737-43.
66. Daosukho C, Chen Y, Noel T, et al. Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. Free Radic Biol Med 2007; 42(12): 1818-25.
67. Burkitt K, Ljungman M. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol Cancer 2008; 7: 24.
68. Burkitt K, Ljungman M. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. Cancer Lett 2007; 253: 131-7.
69. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13: 7413-20.
70. Sylvain V, Lafarge S, Bignon YJ. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 2002; 20: 845-53.
71. Queirós O, Preto A, Pacheco A, et al. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. J Bioenerg Biomembr 2012; 44(1): 141-53.
72. Bueno-Carrazco J, Castro-Leyva V, García-Gomez F, et al. Sodium butyrate increases the effect of the photodynamic therapy: a mechanism that involves modulation of gene expression and differentiation in astrocytoma cells. Childs Nerv Syst 2012; 28(10): 1723-30.
73. Bai LY, Omar HA, Chiu CF, Chi ZP, Hu JL, Weng JR. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemother Pharmacol 2011; 68: 489-96.
74. Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006; 12(17): 5199-206.
75. Kim HD, Jang CY, Choe JM, Sohn J, Kim J. Phenylbutyric acid induces the cellular senescence through an Akt/p21WAF1 signaling pathway. Biochem Biophys Res Com 2012; 422: 213-8.
76. Gu L, Kitamura M. Sensitive detection and monitoring of senescence-associated secretory phenotype by SASP-RAP assay. PLoS ONE 2012; 7(12): e52305.
77. Hauswald S, Duque-Afonso J, Wagner MM, et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 2009; 15(11): 3705-15.
78. Gurtowska N, Kloskowski T, Olkowska J, et al. Carboplatin and sodium butyrate, separate-yes, but combined-never. Acta Pol Pharm 2013; 70(1): 153-61.
79. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-45.
80. Basseri S, Lhoták S, Sharma AM, Austin RC. The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response. J Lipid Res 2009; 50(12): 2486-501.
81. Akash MS, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 2013; 114(3): 525-31.
82. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-9.
83. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801.
84. Roy A, Ghosh A, Jana A, et al. Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson’s disease. PLoS ONE 2012; 7(6): e38113.
85. Qi X, Hosoi T, Okuma Y, Kaneko M, Nomura Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol Pharmacol 2004; 66(4): 899-908.
86. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140(6): 900-17.
87. Segain JP, Raingeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000; 47(3): 397-403.
88. Russo I, Luciani A, De Cicco P, Troncone E, Ciacci C. Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery. PLoS ONE 2012; 7(3): e32841.
89. Park JS, Lee EJ, Lee JC, Kim WK, Kim HS. Anti-inflammatory effects of short chain fatty acids in IFN-γ-stimulated RAW 264.7 murine macrophage cells: Involvement of NF-κ B and ERK signaling pathways. Int Immunopharmacol 2007; 7: 70-7.
90. Kim HJ, Jeong JS, Kim SR, Park SY, Chae HJ, Lee YC. Inhibition of endoplasmic reticulum stress alleviates lipopolysaccharideinduced lung inflammation through modulation of NF-kB/HIF-1a signaling pathway. Sci Rep 2013; 3: 1142.
91. Roque T, Boncoeur E, Saint-Criq V, et al. Proinflammatory effect of sodium 4-phenylbutyrate in deltaF508-cystic fibrosis transmembrane conductance regulator lung epithelial cells: involvement of extracellular signal-regulated protein kinase 1/2 and c-Jun-NH2-terminal kinase signaling. J Pharmacol Exp Ther 2008; 326(3): 949-56.
92. Vij N, Amoako MO, Mazur S, Zeitlin PL. CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2008; 38: 176-84.
93. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994; 84: 339-343.
94. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 1995; 85: 43-9.
95. Ebbel EN, Leymarie N, Schiavo S, et al. Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography / electrochemical array / mass spectrometry and off-line tandem mass spectrometry. Anal Biochem 2010; 399(2): 152-61.
96. Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease. J Biol Chem 2005; 280(1): 556-63.
97. Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington’s disease: a dose-finding study. Mov Disord 2007; 22(13): 1962-4.
98. Petri S, Kiaei M, Kipiani K, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2006; 22(1): 40-9.
99. Del Signore SJ, Amante DJ, Kim J, et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler 2009; 10(2): 85-94.
100. Cudkowicz ME, Andres PL, Macdonald SA, et al. Northeast ALS and National VA ALS Research Consortiums. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009; 10(2): 99-106.
101. Ringe D, Petsko GA. Q&A: What are pharmacological chaperones and why are they interesting? J Biol 2009; 8: 80. Available at (http://jbiol.com/content/8/9/80).
102. Hartl FU, Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo. Nat Struct Mol Biol 2009; 16: 574-81.
103. Leandro P, Gomes CM. Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. Mini Rev Med Chem 2008; 8: 901-11.
104. Arakawa T, Ejima D, Kita Y, Tsumoto K. Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 2006; 1764: 1677-87.
105. Cechowska-Pasko M, Ba_kowski E, Chene P. The effect of hypoxia on the expression of 150 kDa oxygen-regulated protein (ORP 150) in HeLa cells. Cell Physiol Biochem 2006; 17(1-2): 89-96.
106. Kusaczuk M, Cechowska-Pasko M. Molecular chaperone ORP150 in ER stress-related diseases. Curr Pharm Des 2013; 19(15): 2807-18.
107. Zhao J-H, Liu H-L, Lin H-Y, et al. Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases. Perspect Medicin Chem 2007; 1: 39-48.
108. Ben Mosbah I, Alfany-Fernández I, Martel C, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis 2010; 8(1): e52.
109. Perlmutter DH. Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 2002; 52(6): 832-6.
110. Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature 2003; 426: 905-9.
111. Papp E, Csermely P. Chemical chaperones: mechanisms of action and potential use. Handb Exp Pharmacol 2006; 172: 405-16.
112. Teraoka M, Nakaso K, Kusumoto C, et al. Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells. J Clin Biochem Nutr 2012; 51(2): 122-7.
113. Kaul S, Anantharam V, Kanthasamy A, Kanthasamy AG. Wildtype alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death. Brain Res Mol Brain Res 2005; 139(1): 137-52.
114. Baulac S, Lu H, Strahle J, et al. Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains. Mol Neurodegener 2009; 4: 12.
115. Zhou W, Bercury K, Cummiskey J, Luong N, Lebin J, Freed CR. Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J Biol Chem 2011; 286(17): 14941-51.
116. Inden M, Kitamura Y, Takeuchi H, et al. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007; 101(6): 1491-504.
117. Srinivasan K, Sharma SS. Sodium phenylbutyrate ameliorates focal cerebral ischemic/reperfusion injury associated with comorbid type 2 diabetes by reducing endoplasmic reticulum stress and DNA fragmentation. Behav Brain Res 2011; 225(1): 110-6.
118. Xu K, Dai XL, Huang HC, Jiang ZF. Targeting HDACs: A promising therapy for Alzheimer’s disease. Oxid Med Cell Longev 2011; 2011: 143269.
119. Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer’s disease mouse model. Neuropsychopharmacology 2009; 34(7): 1721-32.
120. Kim J, Kleizen B, Choy R, Thinakaran G, Sisodia SS, Schekman RW. Biogenesis of gamma-secretase early in the secretory pathway. J Cell Biol 2007; 179: 951-63.
121. Dries DR, Yu G. Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer’s disease. Curr Alzheimer Res 2008; 5: 132-46.
122. Ricobaraza A, Cuadrado-Tejedor M, Marco S, Pérez-Otaño I, García-Osta A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 2012; 22(5): 1040-50.
123. Ricobaraza A, Cuadrado-Tejedor M, García-Osta A. Long-term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Abeta. Front Biosci (Elite Ed) 2011; 3: 1375-84.
124. Cuadrado-Tejedor M, García-Osta A, Ricobaraza A, Oyarzabal J, Franco R. Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease. Curr Med Chem 2011; 18(36): 5545-53.
125. Suaud L, Miller K, Panichelli AE, Randell RL, Marando CM, Rubenstein RC. 4-Phenylbutyrate stimulates Hsp70 expression through the Elp2 component of elongator and STAT-3 in cystic fibrosis epithelial cells. J Biol Chem 2011; 286(52): 45083-92.
126. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTR. Am J Physiol Cell Physiol 2000; 278: C259-67.
127. Lim M, McKenzie K, Floyd AD, Kwon E, Zeitlin PL. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol 2004; 31(3): 351-7.
128. Prulière-Escabasse V, Planès C, Escudier E, Fanen P, Coste A, Clerici C. Modulation of epithelial sodium channel trafficking and function by sodium 4-phenylbutyrate in human nasal epithelial cells. J Biol Chem 2007; 282(47): 34048-57.
129. Singh OV, Pollard HB, Zeitlin PL. Chemical rescue of ΔF508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells. Mol Cell Proteomics 2008; 7(6): 1099-110.
130. Suaud L, Miller K, Alvey L, et al. ERp29 regulates DeltaF508 and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) trafficking to the plasma membrane in cystic fibrosis (CF) and non-CF epithelial cells. J Biol Chem 2011; 286(24): 21239-53.
131. Singh OV, Vij N, Mogayzel PJ, Jozwik C, Pollard HB, Zeitlin PL. Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells. J Proteome Res 2006; 5(3): 562-71.
132. Nguyen TD, Kim US, Perrine SP. Novel short chain fatty acids restore chloride secretion in cystic fibrosis. Biochem Biophys Res Commun 2006; 342(1): 245-52.
133. Ozcan L, Ergin AS, Lu A, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 2009; 9: 35-51.
134. Sundar Rajan S, Srinivasan V, Balasubramanyam M, Tatu U. Endoplasmic reticulum (ER) stress & diabetes. Indian J Med Res 2007; 125: 411-24.
135. Xiao C, Giacca A, Lewis GF. Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humans. Diabetes 2011; 60(3): 918-24.
136. Luo ZF, Feng B, Mu J, et al. Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: regulation of endoplasmic reticulum stressoxidative activation. Toxicol Appl Pharmacol 2010; 246(1-2): 49-57.
137. Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007; 48(9): 1905-14.
138. Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-89.
139. Boden G, Duan X, Homko C, et al. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulinresistant individuals. Diabetes 2008; 57: 2468-44.
140. Sharma NK, Das SK, Mondal AK, et al. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J. Clin. Endocrinol. Metab 2008; 93: 4532-41.
141. Fu M, Rao M, Bouras T, et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem 2005; 280(17): 16934-41.
142. Yoo EJ, Chung JJ, Choe SS, Kim KH, Kim JB. Down-regulation of histone deacetylases stimulates adipocyte differentiation. J Biol Chem 2006; 281(10): 6608-15.
143. Zuo Y, Qiang L, Farmer SR. Activation of CCAAT/enhancerbinding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptorgamma-associated repression of HDAC1 at the C/ebp alpha gene promoter. J Biol Chem 2006; 281(12): 7960-7.
144. Fan ZC, Tao YX. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. J Cell Mol Med 2009; 13: 3268-82.
145. René P, Le Gouill C, Pogozheva ID, et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J Pharmacol Exp Ther 2010; 335(3): 520-32.
146. Granell S, Mohammad S, Ramanagoudr-Bhojappa R, Baldini G. Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone. Mol Endocrinol 2010; 24: 1805-21.
147. Xiang Z, Litherland SA, Sorensen NB, et al. Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist. Biochemistry 2006; 45: 7277-88.
148. Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 2010; 31: 506-43.
149. Ward NA, Hirst S, Williams J, Findlay JB. Pharmacological chaperones increase the cell-surface expression of intracellularly retained mutants of the melanocortin 4 receptor with unique rescuing efficacy profiles. Biochem Soc Trans 2012; 40(4): 717-20.
150. Granell S, Serra-Juhé C, Martos-Moreno GÁ, et al. A novel melanocortin-4 receptor mutation MC4R-P272L associated with severe obesity has increased propensity to be ubiquitinated in the ER in the face of correct folding. PLoS ONE 2012; 7(12): e50894.
151. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci 2000; 97: 1796-801.
152. Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha 1-antitrypsin in patients with alpha 1-antitrypsin deficiency: A preliminary study. J Pediatr Gastroenterol Nutr 2004; 39: 34-7.
153. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest Ophthalmol Vis Sci 2007; 48(4): 1683-90.
154. Gong B, Zhang LY, Lam DS, Pang CP, Yam GH. Sodium 4-phenylbutyrate ameliorates the effects of cataract-causing mutant gammaD-crystallin in cultured cells. Mol Vis 2010; 16: 997-1003.
155. van der Velden LM, Stapelbroek JM, Krieger E, et al. Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology 2010; 51(1): 286-96.
156. van den Berghe PV, Stapelbroek JM, Krieger E, et al. Reduced expression of ATP7B affected by Wilson disease-causing mutations is rescued by pharmacological folding chaperones 4-phenylbutyrate and curcumin. Hepatology 2009; 50(6): 1783-95.
157. Zode GS, Bugge KE, Mohan K, et al. Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2012; 53(3): 1557-65.
158. Sorrenson B, Suetani RJ, Williams MJA, et al. Functional rescue of mutant ABCA1 proteins by sodium 4-phenylbutyrate. J Lipid Res 2013; 54: 55-62.
159. Hayashi H, Mizuno T, Horikawa R, et al. 4-Phenylbutyrate modulates ubiquitination of hepatocanalicular MRP2 and reduces serum total bilirubin concentration. J Hepatol 2012; 56(5): 1136-44.
160. Summar M. Current strategies for the management of neonatal urea cycle disorders. J Pediatr 2001; 138: S30-9.
161. Leonard JV. Disorders of the urea cycle and related enzymes. 4th rev ed. Springer: Berlin 2006.
162. Burlina AB, Ogier H, Korall H, Trefz FK. Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Mol Genet Metab 2001; 72: 351-5.
163. Gordon N. Ornithine transcarbamylase deficiency: a urea cycle defect. Eur J Paed Neurol 2003; 7: 115-21.
164. Sung MW, Waxman S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res 2007; 27(2): 995-1001.
165. Maslak P, Chanel S, Camacho LH, et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2006; 20: 212-7.
166. Xu TY, Chen RH, Wang P, Zhang RY, Ke SF, Miao CY. 4-Phenyl butyric acid does not generally reduce glucose levels in rodent models of diabetes. Clin Exp Pharmacol Physiol 2010; 37(4): 441-6.
167. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-40.
168. Choi SE, Lee YJ, Jang HJ, et al. A chemical chaperone 4-PBA ameliorates palmitate-induced inhibition of glucose-stimulated insulin secretion (GSIS). Arch Biochem Biophys 2008; 475: 109-14.
169. Gao Z, Yin J, Zhang J, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58: 1509-17.
170. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002; 6(1): 119-26.
171. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157: 484-90.
172. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci 2004; 101(52): 18030-5.
173. Svechnikova I, Ammerpohl O, Ekstr_m TJ. p21waf1/Cip1 partially mediates apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2007; 354(2): 466-71.
174. Hayashi H, Sugiyam Y. 4-Phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology 2007; 45: 1506-16.